Influenza vaccines: Evaluation of the safety profile

Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis

(2018) Tomi O. Sarkanen et al.   SLEEP MEDICINE REVIEWS

Immune responses after live attenuated influenza vaccination

(2018) Kristin G.-I. Mohn et al.   Human Vaccines & Immunotherapeutics

Strategies in recommending influenza vaccination in Europe and US

(2018) Caterina Rizzo et al.   Human Vaccines & Immunotherapeutics

Beliefs and attitudes towards the influenza vaccine in high-risk individuals

(2017) A. J. SANTOS et al.   EPIDEMIOLOGY AND INFECTION

Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16

(2017) Hélène Bricout et al.   Eurosurveillance

Excess mortality in Italy: Should we care about low influenza vaccine uptake?

(2017) Francia Fausto et al.   SCANDINAVIAN JOURNAL OF PUBLIC HEALTH

Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49years

(2017) Roger Baxter et al.   VACCINE

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial

(2017) Anuradha Madan et al.   VACCINE

Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis

(2017) Krista Wilkinson et al.   VACCINE

Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines

(2017) Kathleen M. Neuzil et al.   VACCINE

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study

(2017) John T. Treanor et al.   VACCINE

Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials

(2017) W.E.P. Beyer et al.   VACCINE

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

(2017) Zhaojun Mo et al.   Human Vaccines & Immunotherapeutics

Comparison of side effects of the 2015-2016 high dose, inactivated, trivalent influenza vaccine and standard dose, inactivated, trivalent influenza vaccine in adults >=65 years.

(2017) Anjum S. Kaka et al.   Open Forum Infectious Diseases

Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients

(2016) Natasha B. Halasa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

(2016) Enrique Alcalde-Cabero et al.   BMC Neurology

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England

(2016) Rhian McNaughton et al.   DRUG SAFETY

Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention

(2016) Pedro L. Moro et al.   Expert Opinion On Drug Safety

Influenza immunology evaluation and correlates of protection: a focus on vaccines

(2016) Claudia Maria Trombetta et al.   Expert Review of Vaccines

Evaluating influenza vaccines: progress and perspectives

(2016) Elena Gianchecchi et al.   Future Virology

Anaphylaxis After Immunization of Children and Adolescents in Germany

(2016) Doris Oberle et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons

(2016) Rongxia Li et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children

(2016) Susanna Esposito et al.   VACCINE

Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials

(2016) Aye M. Moa et al.   VACCINE

Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study

(2016) Terry Nolan et al.   VACCINE

Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection

(2016) Hana Hakim et al.   VACCINE

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013−May 31, 2015

(2016) Penina Haber et al.   VACCINE

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States

(2016) Herve Caspard et al.   VACCINE

Vaccinology in the third millennium: scientific and social challenges

(2016) Gregory A Poland et al.   Current Opinion in Virology

Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013–2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®

(2016) Yonggang Shen et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study

(2016) Stephan Bart et al.   Human Vaccines & Immunotherapeutics

Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season

(2015)   AMERICAN JOURNAL OF TRANSPLANTATION

Gene/environment interactions in the pathogenesis of autoimmunity: New insights on the role of Toll-like receptors

(2015) Elena Gianchecchi et al.   AUTOIMMUNITY REVIEWS

Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials

(2015) Claudia Pileggi et al.   BMC INFECTIOUS DISEASES

Long-Term Immunogenicity and Safety of a Conventional Influenza Vaccine in Patients with Type 2 Diabetes

(2015) Yu Bin Seo et al.   Clinical and Vaccine Immunology

Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study

(2015) Sara Ghaderi et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Current and next generation influenza vaccines: Formulation and production strategies

(2015) Peter C. Soema et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children

(2015) J Li-Kim-Moy et al.   Eurosurveillance

Flucelvax (Optaflu) for seasonal influenza

(2015) Ilaria Manini et al.   Expert Review of Vaccines

Safety, immunogenicity and infectivity of new live attenuated influenza vaccines

(2015) Irina Isakova-Sivak et al.   Expert Review of Vaccines

A review of the changes to the licensing of influenza vaccines in Europe

(2015) Leonoor Wijnans et al.   Influenza and Other Respiratory Viruses

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination

(2015) Javier Díez-Domingo et al.   Influenza and Other Respiratory Viruses

Safety of a Pandemic Influenza Vaccine and the Immune Response in Patients with Duchenne Muscular Dystrophy

(2015) Tomoko Saito et al.   INTERNAL MEDICINE

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

(2015) Mahdee Sobhanie et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan

(2015) Yukari Tsurudome et al.   MICROBIOLOGY AND IMMUNOLOGY

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

(2015) Syed Sohail Ahmed et al.   Science Translational Medicine

Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age

(2015) Markus Knuf et al.   VACCINE

The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper

(2015) Neal A. Halsey et al.   VACCINE

Serologic response after vaccination against influenza (A/H1N1)pdm09 in children with renal disease receiving oral immunosuppressive drugs

(2015) Seiji Tanaka et al.   VACCINE

Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia

(2015) Annette K. Regan et al.   VACCINE

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

(2015) Ruvim Izikson et al.   VACCINE

Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50–64 years of age

(2015) Carlos A. DiazGranados et al.   VACCINE

Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial

(2015) Joon Young Song et al.   VACCINE

Guillain-Barré syndrome and influenza vaccines: A meta-analysis

(2015) L.H. Martín Arias et al.   VACCINE

Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial

(2015) Ryo Arakane et al.   VACCINE

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study

(2015) Paul J Turner et al.   BMJ-British Medical Journal

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine - Assessing the immunogenicity and safety in an open label, uncontrolled study

(2015) Louise Roggelin et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine

(2015) Yu Bin Seo et al.   Human Vaccines & Immunotherapeutics

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

(2015) José Garcia-Sicilia et al.   Human Vaccines & Immunotherapeutics

Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

(2015) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study

(2015) Paul J Turner et al.   BMJ-British Medical Journal

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial

(2015) Long Wang et al.   Journal of the Pediatric Infectious Diseases Society

A Comparison of Active Adverse Event Surveillance Systems Worldwide

(2014) Yu-Lin Huang et al.   DRUG SAFETY

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial

(2014) Terry Nolan et al.   JOURNAL OF INFECTIOUS DISEASES

Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households

(2014) Tim K. Tsang et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of Inactivated Quadrivalent and Trivalent Influenza Vaccines in Children 18–47 Months of Age

(2014) Miguel A. Rodriguez Weber et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

(2014) Terry Nolan et al.   VACCINE

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

(2014) Juan Carlos Tinoco et al.   VACCINE

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

(2014) Sharon E. Frey et al.   VACCINE

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months

(2014) Alfonso Carmona Martinez et al.   Human Vaccines & Immunotherapeutics

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

(2014) Keith S Reisinger et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial

(2014) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age

(2014) Natasha B. Halasa et al.   Journal of the Pediatric Infectious Diseases Society

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

(2013) Dorothee Kieninger et al.   BMC INFECTIOUS DISEASES

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France

(2013) Yves Dauvilliers et al.   BRAIN

The evolving history of influenza viruses and influenza vaccines

(2013) Claude Hannoun   Expert Review of Vaccines

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis

(2013) Daniel A Salmon et al.   LANCET

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia

(2013) Meghann McManus et al.   PEDIATRIC BLOOD & CANCER

Safety and Utilization of Influenza Immunization in Children With Inflammatory Bowel Disease

(2013) E. I. Benchimol et al.   PEDIATRICS

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

(2013) Stéphanie Pépin et al.   VACCINE

Live attenuated seasonal and pandemic influenza vaccine in school-age children: A randomized controlled trial

(2013) Brendan Klick et al.   VACCINE

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age

(2013) Geoffrey J. Gorse et al.   VACCINE

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

(2013) Caitlin N. Dodd et al.   VACCINE

Correlates of protection to influenza virus, where do we go from here?

(2013) Rebecca Cox   Human Vaccines & Immunotherapeutics

A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

(2013) Noris Pavia-Ruz et al.   Human Vaccines & Immunotherapeutics

Surveillance for Guillain–Barré Syndrome After Influenza Vaccination Among the Medicare Population, 2009–2010

(2012) Dale R. Burwen et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Preventing influenza in younger children

(2012) S. Esposito et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety of influenza vaccines

(2012) John M. Kelso   Current Opinion in Allergy and Clinical Immunology

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

(2012) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

(2012) Markku Partinen et al.   PLoS One

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

(2012) Hiroyuki Fukase et al.   VACCINE

A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009–2010 season

(2012) Patricia Tennis et al.   VACCINE

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

(2012) Christoph Hatz et al.   VACCINE

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age

(2012) Roger Baxter et al.   VACCINE

The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines

(2012) Janet E. McElhaney et al.   VACCINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

(2012) David P. Greenberg et al.   VACCINE

Live attenuated intranasal influenza vaccine

(2012) Susanna Esposito et al.   Human Vaccines & Immunotherapeutics

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial

(2012) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Live Attenuated Influenza Vaccine (FluMist®; Fluenz™)

(2011) Natalie J. Carter et al.   DRUGS

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years

(2011) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Safety and Immunogenicity of Live Attenuated and Inactivated Influenza Vaccines in Children With Cancer

(2011) Silvana Carr et al.   JOURNAL OF INFECTIOUS DISEASES

A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-STM) in healthy Indian adult population

(2011) AH Kubavat et al.   Journal of Postgraduate Medicine

Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months

(2011) D. M. Skowronski et al.   PEDIATRICS

A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older

(2011) Bruce D. Forrest et al.   VACCINE

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years

(2011) Patricia Tennis et al.   VACCINE

Effectiveness and safety of influenza vaccination in children: European perspective

(2011) Terho Heikkinen et al.   VACCINE

Immunogenicity and safety of intradermal influenza vaccine in children

(2011) Susanna Esposito et al.   VACCINE

A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults

(2011) Stan L. Block et al.   VACCINE

A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups

(2011) Barbara Michiels et al.   VACCINE

The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies

(2011) Christopher S. Ambrose et al.   VACCINE

Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

(2011) Timo Vesikari et al.   VACCINE

Adverse reactions to vaccines

(2010) John M. Kelso et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults

(2010) Ru‐Chien Chi et al.   CLINICAL INFECTIOUS DISEASES

Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing

(2010) Jiang Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children

(2010) Riyadh D. Muhammad et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children

(2010) David W. Scheifele et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety of Influenza Vaccine Administration in Egg-Allergic Patients

(2010) E. Y. Chung et al.   PEDIATRICS

Seasonal influenza and vaccination coverage

(2010) Arnold S. Monto   VACCINE

Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents

(2010) Chun-Yi Lu et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Immune Response to Influenza Vaccine in Children With Inflammatory Bowel Disease

(2009) Ying Lu et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS

(2009) Brigitte Autran et al.   Expert Review of Vaccines

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

(2009) Michael E. Greenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Influenza A (H1N1) Vaccine in Various Age Groups

(2009) Feng-Cai Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

(2009) Pierre J.T. De Villiers et al.   VACCINE

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience

(2008) John Iskander et al.   Expert Review of Vaccines

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza

(2008) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Safety of the Intranasal, Trivalent, Live Attenuated Influenza Vaccine (LAIV) in Children With Intermittent Wheezing in an Open-Label Field Trial

(2008) Manjusha J. Gaglani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age

(2008) Robert B. Belshe et al.   VACCINE

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

(2008) N. Groth et al.   VACCINE